<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05611879</url>
  </required_header>
  <id_info>
    <org_study_id>21416-0-02</org_study_id>
    <nct_id>NCT05611879</nct_id>
  </id_info>
  <brief_title>Neoadjuvant of Tislelizumab Combined With Chemotherapy Followed by Surgery in Unresectable Stage Ⅲ NSCLC</brief_title>
  <official_title>Efficacy and Safety of Tislelizumab With Platinum Doublet Chemotherapy as Neoadjuvant Therapy for Participants With Initially Unresectable Stage III Non-small Cell Lung Cancer: A Single-arm, Phase II Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Tsinghua Chang Gung Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beijing Tsinghua Chang Gung Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this conversion therapy study is to evaluate the safety and efficacy of&#xD;
      neoadjuvant of Tislelizumab combined with platinum doublet for stage III unresectable locally&#xD;
      advanced NSCLC.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">November 1, 2022</start_date>
  <completion_date type="Anticipated">April 30, 2024</completion_date>
  <primary_completion_date type="Anticipated">February 29, 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Resectability rate</measure>
    <time_frame>At time of surgery</time_frame>
    <description>Resectability rate is defined as the percentage of patients who were able to undergo surgery after neoadjuvant therapy.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Major pathological response rate (MPR)</measure>
    <time_frame>At time of surgery</time_frame>
    <description>MPR rate is defined as the percentage of participants having ≤10% viable tumor cells in the resected primary tumor and all resected lymph nodes following completion of neoadjuvant therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pathology complete response rate(pCR)</measure>
    <time_frame>At time of surgery</time_frame>
    <description>pCR rate is defined as the percentage of participants lacking of evidence of viable tumor cells in the pathological examination of resected specimens.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>R0 Resection rate</measure>
    <time_frame>At time of surgery</time_frame>
    <description>R0 Resection rate is defined as the percentage of patients who were able to undergo R0 Resection surgery after neoadjuvant therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Perioperative G3-4 Adverse Events (AEs)</measure>
    <time_frame>Up to 1 month post surgery</time_frame>
    <description>The number of participants experiencing an perioperative G3-4 AE will be assessed.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>NSCLC, Stage III</condition>
  <arm_group>
    <arm_group_label>Neoadjuvant therapy of Tislelizumab with chemotherapy+surgery</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive neoadjuvant Tislelizumab plus double platinum based chemotherapy for 3 cycles, followed by surgical resection.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tislelizumab</intervention_name>
    <description>Tislelizumab: 200mg, IV, day 1 of each 21-day cycle, Neoadjuvant therapy : 3 cycles</description>
    <arm_group_label>Neoadjuvant therapy of Tislelizumab with chemotherapy+surgery</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pemetrexed (Nonsquamous NSCLC) or Paclitaxel/Nab-paclitaxel(Squamous NSCLC)</intervention_name>
    <description>Pemetrexed: 500 mg/m^2, IV, day 1 of each 21-day cycle, 3 cycles. Paclitaxel: 60-75mg/m^2, IV, day 1 of each 21-day cycle, 3 cycles. Nab-paclitaxel: 260mg/m^2, IV, day 1 of each 21-day cycle, 3 cycles.</description>
    <arm_group_label>Neoadjuvant therapy of Tislelizumab with chemotherapy+surgery</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>AUC 5 mg/mL/min by IV infusion Q3W, given on cycle day 2.</description>
    <arm_group_label>Neoadjuvant therapy of Tislelizumab with chemotherapy+surgery</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Written informed consent provided.&#xD;
&#xD;
          -  Unresectable stage III non-small cell lung cancer confirmed by histopathology or&#xD;
             cytology.&#xD;
&#xD;
          -  ECOG score is 0 or 1.&#xD;
&#xD;
          -  Adequate hematological function, liver function and renal function.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previously received systemic anti-tumor therapy for non-small cell lung cancer.&#xD;
&#xD;
          -  history or current (non-infectious) pneumonia/interstitial pneumonia requiring steroid&#xD;
             treatment.&#xD;
&#xD;
          -  History or active pulmonary tuberculosis.&#xD;
&#xD;
          -  Active infections that require systemic treatment.&#xD;
&#xD;
          -  History or suspected autoimmune disease or immune deficiency who, in the judgment of&#xD;
             the investigator, cannot tolerate immunotherapy.&#xD;
&#xD;
          -  Untreated active Hepatitis B.&#xD;
&#xD;
          -  Has a known history of human immunodeficiency virus (HIV) infection (HIV 1/2 antibody&#xD;
             positive).&#xD;
&#xD;
          -  Grade 3 or above peripheral neuropathy.&#xD;
&#xD;
          -  Severe allergic history to pemetrexed, paclitaxel, albumin-bound paclitaxel,&#xD;
             carboplatin or other preventive drugs.&#xD;
&#xD;
          -  Underlying severe or uncontrolled disease.&#xD;
&#xD;
          -  Malignant tumors other than NSCLC within 5 years.&#xD;
&#xD;
          -  Any medical condition requiring systemic treatment with corticosteroids (prednisone or&#xD;
             equivalent at a dose of &gt;10mg/ day) or other immunosuppressive agents within 14 days&#xD;
             prior to treatment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Fan Yang, Dr.</last_name>
    <phone>+86-10-56112345</phone>
    <email>Yfa01087@btch.edu.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Beijing Tsinghua Chang Gung Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fan Yang, Dr.</last_name>
      <phone>+86-10-56112345</phone>
      <email>Yfa01087@btch.edu.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2021</verification_date>
  <study_first_submitted>November 4, 2022</study_first_submitted>
  <study_first_submitted_qc>November 4, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">November 10, 2022</study_first_posted>
  <last_update_submitted>November 4, 2022</last_update_submitted>
  <last_update_submitted_qc>November 4, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">November 10, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Pemetrexed</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

